FDA Should Stay Out Of Value, Pricing Discussions, Experts Say

By Beth Wang / December 5, 2019 at 12:30 PM
Biopharmaceutical venture fund and managed care organization experts believe FDA should stay out of the medical product pricing and value arenas and instead let the marketplace determine value. FDA put out a guidance document last year clarifying the type of health care economic information (HCEI) that drug makers can send to payers, and the agency has increasingly engaged in discussions on the issue. But, up to now, FDA has largely put the burden of showing value on industry, the experts...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.